Translational control of the fibroblast phenotype in IPF
Translational control of the fibroblast phenotype in IPF
批准号:
8375051
负责人:
Peter B Bitterman
金额:
$47.79万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
3&apos Untranslated RegionsAlveolarBindingBinding ProteinsBiologicalBiological MarkersBlood CirculationCancer BiologyCell CycleCell ProliferationCell divisionCellsClinical TrialsDataDifferentiation and GrowthDiseaseEctodermElementsEpithelial CellsExcisionFibroblastsFrequenciesGene ExpressionGene Expression ProfileGenesGenetically Engineered MouseGrowthGrowth FactorGrowth Factor ReceptorsHamman-Rich syndromeHumanInstructionIntegrinsKineticsLesionLinkLungMalignant NeoplasmsMalignant neoplasm of lungMapsMediatingMessenger RNAMicroRNAsMolecularMolecular AnalysisMolecular TargetNormal CellOncogenesOntologyOperonPathway interactionsPatientsPatternPhenotypePhysiologicalProcessProductionPropertyProteinsPublicationsRNARNA BindingRecruitment ActivityRefractoryRegulationRegulatory ElementReport (document)ReporterRibosomesRoleSamplingSignal TransductionSiteSourceSpecimenStructure of parenchyma of lungSystemSystems BiologyTestingTissuesTranscriptTranslatingTranslation InitiationTranslationsZebrafishbasecancer cellepithelial to mesenchymal transitiongenome-wideinsightlung injurymalignant breast neoplasmmorphogensprototyperesponsetheories
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Fibroblasts populating fibrotic lesions manifest an unexplained autonomy for growth and survival signals.
Fibrotic fibroblasts arise from at least 3 sources: the circulation, resident fibroblasts and the epithelial to
mesenchymal transition (EMT). However, the connection between fibroblast origin and autonomous function
remains undefined. Here we propose to study lung fibroblasts from patients with Idiopathic Pulmonary
Fibrosis and elucidate the mechanism of autonomous function using our discoveries in cancer biology as a
guide. In studies of human breast and lung cancer, we discovered that autonomy is conferred by
pathological regulation of the translation initiation machinery, designated elF4F. In cancer cells, elF4F
serves to integrate growth and survival signals from oncogenes by selectively recruiting ribosomes to groups
of transcripts that confer autonomy. Our preliminary data indicate that aberrant activation of elF4F is a
property of IFF fibroblasts; that activating elF4F in fibroblasts stimulates cell cycle entry in the absence of
growth factors; that mice genetically engineered to lack negative regulators of elF4F have an exaggerated
fibrotic response to lung injury; and that activating elF4F in zebrafish ectoderm explants triggers EMT. We
therefore hypothesize that pathological translational control contributes to the fibrotic phenotype in IPF by
mediating EMT and the emergence of proliferative autonomy. The framework for testing this hypothesis is
the post transcriptional operon theory, which posits that recruitment of ribosomes to mRNA is governed by
regulatory elements in the transcript 5' and 3' UTR. Acting alone or in concert with trans-acting protein or
micro RNA binding partners, RNA regulatory elements provide the instructions for ribosome recruitment. To
discover how these ribosome recruitment instructions might be altered in IPF, we propose 2 specific aims: 1)
Define the mechanisms linking pathological translational control with IPF fibroblast proliferative autonomy; 2)
Examine translational control of alveolar epithelial cell EMT and test its relevance to IPF. Our studies will
provide the first systems level, genome-wide examination of the fibrotic fibroblast phenotype based on a
quantitiative assesment of which mRNA are being actively translated into protein.
RELEVANCE (See instructions):
If successful, our studies will precisely identify derangements in the gene expression pathway that confer IPF
fibroblasts with a pathological phenotype and provide insight into the role of EMT in the genesis of fibroblasts
in the IPF lung.This information has the potential to reveal new classes of molecular targets for antifibrotic
therapy and unveil new disease-relevant biomarkers for clinical trials.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of fibrotic extracellular matrix in generating the IPF Fibroblast
-
批准号:9187880
-
项目类别:
-
资助金额:$46.87万
-
财政年份:2014
-
负责人:Peter B Bitterman
-
依托单位:
Role of fibrotic extracellular matrix in generating the IPF Fibroblast
-
批准号:8794621
-
项目类别:
-
资助金额:$46.87万
-
财政年份:2014
-
负责人:Peter B Bitterman
-
依托单位:
Role of fibrotic extracellular matrix in generating the IPF Fibroblast
-
批准号:8982246
-
项目类别:
-
资助金额:$46.87万
-
财政年份:2014
-
负责人:Peter B Bitterman
-
依托单位:
Translational control of the fibroblast phenotype in IPF
-
批准号:8242756
-
项目类别:
-
资助金额:$47.79万
-
财政年份:2011
-
负责人:Peter B Bitterman
-
依托单位:
Translational control of the fibroblast phenotype in IPF
-
批准号:7680428
-
项目类别:
-
资助金额:$34.21万
-
财政年份:2009
-
负责人:Peter B Bitterman
-
依托单位:
Translational Control in IPF
-
批准号:8119476
-
项目类别:
-
资助金额:$41.97万
-
财政年份:2008
-
负责人:Peter B Bitterman
-
依托单位:
Translational Control in IPF
-
批准号:7689897
-
项目类别:
-
资助金额:$44.57万
-
财政年份:2008
-
负责人:Peter B Bitterman
-
依托单位:
Translational Control in IPF
-
批准号:7899902
-
项目类别:
-
资助金额:$43.34万
-
财政年份:2008
-
负责人:Peter B Bitterman
-
依托单位:
Translational Control in IPF
-
批准号:7459477
-
项目类别:
-
资助金额:$45.8万
-
财政年份:2008
-
负责人:Peter B Bitterman
-
依托单位:
Summer Research at the University of Minnesota Medical School
-
批准号:8534803
-
项目类别:
-
资助金额:$15.75万
-
财政年份:2007
-
负责人:Peter B Bitterman
-
依托单位:
Summer Research at the University of Minnesota Medical School
-
批准号:8680313
-
项目类别:
-
资助金额:$15.75万
-
财政年份:2007
-
负责人:Peter B Bitterman
-
依托单位:
Translational State Assay for Human Samples
-
批准号:7343407
-
项目类别:
-
资助金额:$18.88万
-
财政年份:2007
-
负责人:Peter B Bitterman
-
依托单位:
Summer Research at the University of Minnesota Medical School
-
批准号:8838851
-
项目类别:
-
资助金额:$15.75万
-
财政年份:2007
-
负责人:Peter B Bitterman
-
依托单位:
Summer Research at the University of Minnesota Medical School
-
批准号:8366779
-
项目类别:
-
资助金额:$15.75万
-
财政年份:2007
-
负责人:Peter B Bitterman
-
依托单位:
Translational State Assay for Human Samples
-
批准号:7741246
-
项目类别:
-
资助金额:$18.69万
-
财政年份:2007
-
负责人:Peter B Bitterman
-
依托单位:
Antifibrotic Drug Discovery in Acute Lung Injury
-
批准号:6879590
-
项目类别:
-
资助金额:$45.18万
-
财政年份:2004
-
负责人:Peter B Bitterman
-
依托单位:
Antifibrotic Drug Discovery in Acute Lung Injury
-
批准号:7036607
-
项目类别:
-
资助金额:$46.93万
-
财政年份:2004
-
负责人:Peter B Bitterman
-
依托单位:
Antifibrotic Drug Discovery in Acute Lung Injury
-
批准号:7189049
-
项目类别:
-
资助金额:$46.36万
-
财政年份:2004
-
负责人:Peter B Bitterman
-
依托单位:
Antifibrotic Drug Discovery in Acute Lung Injury
-
批准号:6760518
-
项目类别:
-
资助金额:$44.98万
-
财政年份:2004
-
负责人:Peter B Bitterman
-
依托单位:
Molecular Targets for Drug Discovery in IPF
-
批准号:6794765
-
项目类别:
-
资助金额:$74.25万
-
财政年份:2003
-
负责人:Peter B Bitterman
-
依托单位:
海外基金